Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville.
School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
JAMA Netw Open. 2024 Aug 1;7(8):e2435535. doi: 10.1001/jamanetworkopen.2024.35535.
One-third of older adults in the US have depression, often treated with psychotherapy and antidepressants. Previous studies suggesting an increased risk of falls and related injuries (FRI) associated with antidepressant use may be affected by confounding by indication or immortal time bias.
To evaluate the association between FRI risk and first-line treatments in older adults with depression.
DESIGN, SETTING, AND PARTICIPANTS: This cohort study used a target trial emulation framework with a cloning-censoring-weighting approach with Medicare claims data from 2016 to 2019. Participants included fee-for-service beneficiaries aged 65 years or older with newly diagnosed depression. Data were analyzed from October 1, 2023, to March 31, 2024.
First-line depression treatments including psychotherapy, sertraline, escitalopram, citalopram, mirtazapine, duloxetine, trazodone, fluoxetine, bupropion, paroxetine, and venlafaxine.
One-year FRI rate, restricted mean survival time (RMST), and adjusted hazard ratio (aHR) with 95% CI.
Among 101 953 eligible beneficiaries (mean [SD] age, 76 [8] years), 63 344 (62.1%) were female, 7404 (7.3%) were Black individuals, and 81 856 (80.3%) were White individuals. Compared with the untreated group, psychotherapy use was not associated with FRI risk (aHR, 0.94 [95% CI, 0.82-1.17]), while other first-line antidepressants were associated with a decreased FRI risk (aHR ranged from 0.74 [95% CI, 0.59-0.89] for bupropion to 0.83 [95% CI, 0.67-0.98] for escitalopram). The FRI incidence ranged from 63 (95% CI, 53-75) per 1000 person-year for those treated with bupropion to 87 (95% CI, 83-90) per 1000 person-year for those who were untreated. The RMST ranged from 349 (95% CI, 346-350) days for those who were untreated to 353 (95% CI, 350-356) days for those treated with bupropion.
In this cohort study of older Medicare beneficiaries with depression, first-line antidepressants were associated with a decreased FRI risk compared with untreated individuals. These findings provide valuable insights into their safety profiles, aiding clinicians in their consideration for treating depression in older adults.
美国三分之一的老年人患有抑郁症,通常采用心理治疗和抗抑郁药进行治疗。先前的研究表明,抗抑郁药的使用与跌倒和相关伤害(FRI)风险增加有关,这可能受到指示混淆或不朽时间偏倚的影响。
评估在患有抑郁症的老年人中,FRI 风险与一线治疗之间的关联。
设计、设置和参与者:这项队列研究使用了目标试验模拟框架,采用克隆-删失加权方法,使用 2016 年至 2019 年的医疗保险索赔数据。参与者包括新诊断为抑郁症的 65 岁或以上的收费服务受益人。数据分析于 2023 年 10 月 1 日至 2024 年 3 月 31 日进行。
一线抑郁症治疗包括心理治疗、舍曲林、依地普仑、西酞普兰、米氮平、度洛西汀、曲唑酮、氟西汀、安非他酮、帕罗西汀和文拉法辛。
一年 FRI 发生率、受限平均生存时间(RMST)和调整后的危险比(aHR)及其 95%置信区间。
在 101953 名符合条件的受益人中(平均[SD]年龄,76[8]岁),63344 名(62.1%)为女性,7404 名(7.3%)为黑人,81856 名(80.3%)为白人。与未治疗组相比,心理治疗的使用与 FRI 风险无关(aHR,0.94[95%CI,0.82-1.17]),而其他一线抗抑郁药与降低的 FRI 风险相关(aHR 范围为 0.74[95%CI,0.59-0.89]对于安非他酮至 0.83[95%CI,0.67-0.98]对于依地普仑)。FRI 的发生率范围为每 1000 人年 63(95%CI,53-75)例,对于接受安非他酮治疗的患者,每 1000 人年 87(95%CI,83-90)例,对于未接受治疗的患者。RMST 范围为每 1000 人年 349(95%CI,346-350)天,对于未接受治疗的患者,至每 1000 人年 353(95%CI,350-356)天,接受安非他酮治疗的患者。
在这项针对患有抑郁症的老年医疗保险受益人的队列研究中,与未接受治疗的个体相比,一线抗抑郁药与降低 FRI 风险相关。这些发现为它们的安全概况提供了有价值的见解,有助于临床医生在为老年人治疗抑郁症时进行考虑。